Zimbabwe has turned down a major US health deal valued at $367m (£272m) over five years over Washington's demand for confidential biological samples.
This rejection came to light following a government memo dated December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the deal was "skewed".
A government spokesman has since stated that the United States was demanding access to genetic material for research and commercial purposes but refused to share the benefits from any future medical innovations.
"We will now turn to the difficult and regrettable process of winding down our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had donated over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged more dialogue to secure a agreement suitable to all parties so the nation's vital HIV programme can proceed.
Wider Context
This development follows a similar situation in Kenya, where a high court blocked a similar deal with the US following legal challenges were raised about the security of citizens' health data.
Since resuming office last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had administered aid for the US government, but Trump claimed its expenditure was "wasteful" and his government was seeking direct bilateral deals to boost openness and accountability.
According to reports, 16 African countries have to date agreed to similar health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Declined Deal
The money for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership could have provided significant advantages for the people of Zimbabwe, especially the 1.2 million currently on antiretroviral therapy through US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, with no corresponding assurance of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might result from that shared data," he stated.
"Put simply, our country would supply the raw materials for medical research without any certainty that the resulting innovations would be available to our people if a future pandemic emerge."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one deals were upending structures already established through the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to deal with future pandemics.
"This system is intended to guarantee that when a country contributes its samples, the benefits – such as medicines and cures – are shared equitably, not monopolised solely by those with the capability to create them."
The government's concerns regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome ongoing dialogue with our American counterparts on how future co-operation could be designed in a manner that respects the independence and interests of both nations."
Health Experts Response
Medical experts expressed it recognised the official position, but urged that negotiations must proceed considering much of the country's Aids initiatives were funded by international support.
"Where specific concerns exist, including those relating to data governance or agreement terms, these can frequently be resolved through detailed discussion and mutually agreed protections," the group added.
The situation emphasises the continuing challenges between accepting crucial foreign assistance and safeguarding national sovereignty in an increasingly interconnected world.